X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49) 49
index medicus (45) 45
hematology (31) 31
aged (27) 27
female (24) 24
male (24) 24
oncology (24) 24
prognosis (20) 20
multiple myeloma - drug therapy (19) 19
treatment outcome (19) 19
middle aged (17) 17
multiple myeloma (17) 17
abridged index medicus (15) 15
article (15) 15
bortezomib (15) 15
multiple myeloma - mortality (14) 14
multiple myeloma - genetics (13) 13
survival (13) 13
cancer (12) 12
disease-free survival (12) 12
expression (12) 12
myeloma (12) 12
thalidomide (12) 12
aged, 80 and over (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
clinical trials (10) 10
follow-up studies (10) 10
multiple myeloma - therapy (10) 10
research (10) 10
survival rate (10) 10
adult (9) 9
clinical trials and observations (9) 9
multiple myeloma - pathology (9) 9
risk factors (9) 9
thalidomide - administration & dosage (9) 9
disease (8) 8
kaplan-meier estimate (8) 8
multiple myeloma - diagnosis (8) 8
patients (8) 8
time factors (8) 8
chemotherapy (7) 7
chromosome aberrations (7) 7
gene expression (7) 7
gene expression profiling (7) 7
monoclonal gammopathy (7) 7
stem-cell transplantation (7) 7
survival analysis (7) 7
antineoplastic agents - therapeutic use (6) 6
disease progression (6) 6
genetic aspects (6) 6
prospective studies (6) 6
analysis (5) 5
antineoplastic agents - administration & dosage (5) 5
care and treatment (5) 5
classification (5) 5
clinical trials as topic (5) 5
combined modality therapy (5) 5
dose-response relationship, drug (5) 5
genes (5) 5
impact (5) 5
lymphoid neoplasia (5) 5
multiple-myeloma (5) 5
multivariate analysis (5) 5
research design (5) 5
risk assessment (5) 5
stem cells (5) 5
thalidomide - therapeutic use (5) 5
therapy (5) 5
undetermined significance (5) 5
abnormalities (4) 4
animals (4) 4
boronic acids - administration & dosage (4) 4
criteria (4) 4
cytotoxicity (4) 4
dexamethasone - administration & dosage (4) 4
drug dosages (4) 4
drug therapy (4) 4
flow cytometry (4) 4
immunohistochemistry (4) 4
metastasis (4) 4
multiple myeloma - epidemiology (4) 4
multiple myeloma - metabolism (4) 4
neoplasm recurrence, local - drug therapy (4) 4
progression (4) 4
pyrazines - administration & dosage (4) 4
recurrence (4) 4
risk (4) 4
risk groups (4) 4
thalidomide - analogs & derivatives (4) 4
transplantation (4) 4
angiogenesis (3) 3
angiogenesis inhibitors - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
apoptosis (3) 3
biomarkers, tumor - genetics (3) 3
blotting, western (3) 3
bone marrow (3) 3
bone marrow - pathology (3) 3
cancer therapies (3) 3
case-control studies (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10068, pp. 519 - 527
Journal Article
2006, 2nd ed., ISBN 0824723392, 617
Book
Clinical Cancer Research, ISSN 1078-0432, 07/2008, Volume 14, Issue 14, pp. 4358 - 4367
Journal Article
Leukemia, ISSN 0887-6924, 01/2019, Volume 33, Issue 1, pp. 159 - 170
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1877 - 1877
Abstract Introduction: Both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are associated with marked racial disparities;... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2018, Volume 24, Issue 12, pp. 2913 - 2919
Purpose: Mesenchymal stem cells (MSC) are an essential component of the bone marrow microenvironment and have shown to support cancer evolution in multiple... 
MICROENVIRONMENT | ONCOLOGY | HIGH-RISK | BONE-MARROW | ENDOTHELIAL-CELLS | DISEASE | UNDETERMINED SIGNIFICANCE | MONOCLONAL GAMMOPATHY | MODEL | TUMOR-GROWTH | CANCER | Mesenchyme | Genes | Multiple myeloma | Monoclonal gammopathy | Gammopathy | Gene expression | Patients | Bone cancer | Experimental design | Stem cells | Smoldering | Bone marrow | Plasma cells | Remission | Health risk assessment | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3897 - 3897
Abstract Introduction: Poor prognosis and drug resistance in multiple myeloma (MM) is associated with increased mutational load. APOBEC3B is a major... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3168 - 3168
Abstract Introduction Recently a number of clinical trials have reported on a comparison between autologous stem cell transplantation (ASCT) for multiple... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2684 - 2692
PurposeCPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a... 
AML | ADULT PATIENTS | THERAPY | ONCOLOGY | CYTARABINEDAUNORUBICIN | MOLAR RATIO | FORMULATION | CYTOTOXICITY | CHEMOTHERAPY | CLINICAL-SIGNIFICANCE | AGE | RAPID COMMUNICATION
Journal Article
Haematologica, ISSN 0390-6078, 09/2012, Volume 97, Issue 9, pp. 1348 - 1356
Journal Article
Journal Article